ABSI: Reports Interim Phase 1 Data
Absci reports interim phase 1 data from its trial of ABS-201, an investigational anti-prolactin receptor antibody, showing favorable safety data.
Absci Announces Interim Phase 1 Data From Its Trial Of ABS-201, An Investigational Anti-Prolactin Receptor Antibody; Study Medication Appears Well Tolerated, With Favorable Safety Data Across All Blinded Single Ascending Dose Cohorts